3D-printed supercapacitor-powered electrochemiluminescent protein immunoarray.
3D-printed supercapacitor-powered electrochemiluminescent protein immunoarray.
复制标题
DOI：
10.1016/j.bios.2015.09.017
复制
发表时间：
2016-03-15
影响因子：
12.6
通讯作者：
Rusling JF
中科院分区：
文献类型：
--
作者：
Kadimisetty K;Mosa IM;Malla S;Satterwhite-Warden JE;Kuhns TM;Faria RC;Lee NH;Rusling JF
在这里，我们报道了一种低成本、灵敏、超级电容器供电的电化学发光(ECL)蛋白免疫阵列，该阵列由廉价的三维(3D)打印机制造。该免疫传感器可在35分钟内检测到血清中的三种肿瘤生物标志物蛋白。3D打印设备采用具有重力流动的手动屏幕打印碳传感器，用于样品/试剂的输送和清洗。在抗体包被的碳传感器上捕获血清中的前列腺癌生物标志物蛋白、前列腺特异性抗原(PSA)、前列腺特异性膜抗原(PSMA)和血小板因子-4(PF-4)，然后在夹心免疫分析中传递检测抗体包被的Ru(Bpy)32+(RuBPY)掺杂的二氧化硅纳米颗粒。利用超级电容功率，利用三丙胺(TPrA)共反应物电化学氧化二氧化硅纳米颗粒中的RuBPY激发ECL光，并用CCD摄像机捕捉到ECL光。超级电容器在两次测试之间使用廉价的太阳能电池进行快速光充电。未稀释的小牛血清中3种蛋白质的检出限为300~500fgmL−1。6份前列腺癌患者血清样品的检测结果与常规单蛋白ELISA检测结果具有较好的相关性。这项技术可以在资源有限的情况下提供灵敏的现场癌症诊断测试，只需要中等水平的培训。
Herein we report a low cost, sensitive, supercapacitor-powered electrochemiluminescent (ECL) protein immunoarray fabricated by an inexpensive 3-dimensional (3D) printer. The immunosensor detects three cancer biomarker proteins in serum within 35 min. The 3D-printed device employs hand screen printed carbon sensors with gravity flow for sample/reagent delivery and washing. Prostate cancer biomarker proteins, prostate specific antigen (PSA), prostate specific membrane antigen (PSMA) and platelet factor-4 (PF-4) in serum were captured on the antibody-coated carbon sensors followed by delivery of detection-antibody-coated Ru(bpy)32+ (RuBPY)-doped silica nanoparticles in a sandwich immunoassay. ECL light was initiated from RuBPY in the silica nanoparticles by electrochemical oxidation with tripropylamine (TPrA) co-reactant using supercapacitor power and ECL was captured with a CCD camera. The supercapacitor was rapidly photo-recharged between assays using an inexpensive solar cell. Detection limits were 300–500 fg mL−1 for the 3 proteins in undiluted calf serum. Assays of 6 prostate cancer patient serum samples gave good correlation with conventional single protein ELISAs. This technology could provide sensitive onsite cancer diagnostic tests in resource-limited settings with the need for only moderate-level training.